clinical trial · NCT02723994
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
LeukemiaRuxolitinibAsparaginase Erwinia ChrysanthemiCyclophosphamideCytarabineDexamethasoneDoxorubicinLeucovorin CalciumMercaptopurine
brief summary
This is a nonrandomized study of ruxolitinib in combination with a standard multi-agent chemotherapy regimen for the treatment of B-cell acute lymphoblastic leukemia. Part 1 of the study will optimize the dose of study drug (ruxolitinib) in combination with the chemotherapy regimen. Part 2 will evaluate the efficacy of combination chemotherapy and ruxolitinib at the recommended dose determined in Part 1.
started
Sep 30, 2016
primary completion
Mar 3, 2026
completion
Mar 3, 2026
last updated
Mar 11, 2026
official title
A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol